Axsome Therapeutics Inc (NASDAQ:AXSM) has been assigned a consensus recommendation of “Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $155.50.

Several research analysts recently commented on AXSM shares. LADENBURG THALM/SH SH increased their price target on Axsome Therapeutics from $165.00 to $186.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Guggenheim increased their price target on Axsome Therapeutics from $158.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. SunTrust Banks increased their price target on Axsome Therapeutics from $145.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Cantor Fitzgerald raised their price objective on Axsome Therapeutics from $125.00 to $131.00 and gave the company an “overweight” rating in a research report on Monday, April 27th. Finally, William Blair reaffirmed a “buy” rating on shares of Axsome Therapeutics in a research report on Monday, April 6th.

Large investors have recently added to or reduced their stakes in the stock. Total Clarity Wealth Management Inc. acquired a new stake in Axsome Therapeutics during the 4th quarter worth approximately $25,000. NEXT Financial Group Inc bought a new position in Axsome Therapeutics during the 4th quarter worth $31,000. Jacobi Capital Management LLC bought a new position in Axsome Therapeutics during the 4th quarter worth $31,000. Lindbrook Capital LLC bought a new position in shares of Axsome Therapeutics in the 4th quarter valued at $41,000. Finally, Huntington National Bank bought a new position in shares of Axsome Therapeutics in the 4th quarter valued at $52,000. 60.07% of the stock is owned by institutional investors and hedge funds.

NASDAQ:AXSM opened at $86.88 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 9.00 and a current ratio of 9.00. The company has a market cap of $3.04 billion, a PE ratio of -33.94 and a beta of 3.30. Axsome Therapeutics has a 52-week low of $13.64 and a 52-week high of $109.94. The stock has a 50-day simple moving average of $72.24 and a 200 day simple moving average of $69.22.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.28). On average, research analysts predict that Axsome Therapeutics will post -2.41 earnings per share for the current fiscal year.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

See Also: Hang Seng Index (HSI)

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.